R. Habib

发表

Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers.

S. Self, D. Stablein, S. Buchbinder, 2001, The Journal of infectious diseases.

Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection

B. Autran, J. Tartaglia, P. Chong, 1999 .

Intravenous γ-globulin in myasthenia gravis: Interaction with anti-acetylcholine receptor autoantibodies

R. Liblau, J. Bach, P. Gajdos, 1991, Journal of Clinical Immunology.

A Phase 1/2 Comparative Vaccine Trial of the Safety and Immunogenicity of a CRF01_AE (Subtype E) Candidate Vaccine: ALVAC-HIV (vCP1521) Prime With Oligomeric gp160 (92TH023/LAI-DID) or Bivalent gp120 (CM235/SF2) Boost

Jerome H. Kim, D. Birx, R. Paris, 2007, Journal of acquired immune deficiency syndromes.

Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120.

M. L. Clements-Mann, D. Montefiori, D. Stablein, 2001, The Journal of infectious diseases.

Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1.

D. Montefiori, D. Stablein, A. Lazzarin, 2000, AIDS research and human retroviruses.

Highly Active Antiretroviral Therapy 1-Infected Patients Treated with Prolonged Human Immunodeficiency Virus Type vCP 1452 and Recombinant gp 160 in Newly Safety and Immunogenicity of ALVAC

D. Ho, J. Binley, A. Hurley, 2002 .

Safety and Immunogenicity of ALVAC vCP1452 and Recombinant gp160 in Newly Human Immunodeﬁciency Virus Type 1-Infected Patients Treated with Prolonged Highly Active Antiretroviral Therapy

D. Ho, J. Binley, X. Jin, 2002 .

Assessment of mucosal immunity to HIV-1

F. Wegmann, R. Shattock, A. Spetz, 2010, Expert review of vaccines.

Use of predictive markers of HIV disease progression in vaccine trials.

S. Gurunathan, J. Tartaglia, L. Corey, 2009, Vaccine.

Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients

C. Rouzioux, Y. Lévy, J. Guillet, 2005, AIDS.

CCR5 or CXCR4 use influences the relationship between CD4 cell depletion, NKp44L expression and NK cytotoxicity in SHIV-infected macaques

P. Debré, V. Vieillard, J. Calvo, 2008, AIDS.

Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein.

M. McElrath, P. Goepfert, Yuwei Zhu, 2004, The Journal of infectious diseases.

A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024).

J. Lawrence, A. Zolopa, R. Bosch, 2006, The Journal of infectious diseases.